Jefferies Lifts Price Target On UnitedHealth (UNH)
Get Alerts UNH Hot Sheet
Price: $430.67 +0.37%
Rating Summary:
31 Buy, 6 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 22 | New: 8
Rating Summary:
31 Buy, 6 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 13 | Down: 22 | New: 8
Join SI Premium – FREE
Jefferies raised estimates and its price target on UnitedHealth Group (NYSE: UNH) from $48 to $50, but maintained its Hold rating.
"UNH was the first large cap MCO to report 1Q11 results, and they far surpassed expectations. The company beat 1Q EPS by 25%+, raised 2011 EPS guidance by 11% (6% above consensus), and showed strong fundamental momentum. Thursday's 8% surge captured UNH's upside, in our view, but other MCOs such as HS, HNT, and HUM could still see further share appreciation."
FY11 EPS goes from $4.08 to $4.21.
For more ratings news on UnitedHealth Group click here and for the rating history of UnitedHealth Group click here.
Shares of UnitedHealth Group closed at $47.81 yesterday.
"UNH was the first large cap MCO to report 1Q11 results, and they far surpassed expectations. The company beat 1Q EPS by 25%+, raised 2011 EPS guidance by 11% (6% above consensus), and showed strong fundamental momentum. Thursday's 8% surge captured UNH's upside, in our view, but other MCOs such as HS, HNT, and HUM could still see further share appreciation."
FY11 EPS goes from $4.08 to $4.21.
For more ratings news on UnitedHealth Group click here and for the rating history of UnitedHealth Group click here.
Shares of UnitedHealth Group closed at $47.81 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies on Bank of America (BAC): 'Average loans remained solid'
- UBS Reiterates Buy Rating on Boot Barn (BOOT), Expects Q1 Earnings Beat
- UBS Reiterates Buy Rating on Boeing (BA) on Increased Confidence in 2026 Deliveries
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share